Dural non-Hodgkin’s lymphomas
Autor: | E E Leenman, L G Babicheva, N. V. Ilyin, V V Ryabchikova, Irina V. Poddubnaya, Yu. N. Vinogradova, V. V. Baikov |
---|---|
Rok vydání: | 2016 |
Předmět: |
Cancer Research
Pathology medicine.medical_specialty Dura mater medicine.medical_treatment non-hodgkin lymphoma dura mater lcsh:RC254-282 Lesion stomatognathic system hemic and lymphatic diseases medicine Disseminated disease radiotherapy primary central nervous system lymphoma business.industry Primary central nervous system lymphoma Immunosuppression lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens medicine.disease marginal zone lymphoma Lymphoma medicine.anatomical_structure Lymphatic system Oncology Monoclonal prognosis medicine.symptom business |
Zdroj: | Современная онкология, Vol 18, Iss 2, Pp 19-26 (2016) |
ISSN: | 1815-1434 |
DOI: | 10.26442/1815-1434_2016.2.19-26 |
Popis: | Primary presentation of intradural non-Hodgkin lymphoma (PDL) is rare. Most published cases of PDL are single-patient reports. This lesion occurs more often in middle-aged women, in contrast to brain parenchyma primary central nervous system lymphoma (PCNSL), which has a slight male predilection. In contrast with parenchymal PCNSL, there has been no clear association between acquired and congenital immunosuppression and the development of PDL. The pathogenesis of PDL is not well understood because the dura is devoid of any lymphoid tissue. One hypothesis is that a benign inflammatory condition of the dura could attract polyclonal lymphocytes from which a monoclonal lymphoma could arise. B-cell lymphomas of mucosa-associated lymphoid tissue (MALT) have been recognized as an important pathologic subtype. A PDL is more indolent and has a better prognosis than parenchymal PCNSL or systemic lymphoma with CNS metastasis. However, further studies with longer clinical follow up are necessary to assess the final outcome in these patients. In general, patients with marginal zone lymphoma have a favorable outcome, with a 5-year overall survival rate greater than 86%, without significant differences between gastrointestinal and nongastrointestinal and between localized and disseminated disease. |
Databáze: | OpenAIRE |
Externí odkaz: |